Properties of hydrogen peroxide-induced histamine release from rat mast cells.

Biochem Pharmacol

Department of Medicinal Biochemistry, Faculty of Pharmaceutial Sciences, Okayama University, Tsushima-naka 1-1, Okayama 700, Japan.

Published: March 1980

Incubation of rat peritoneal mast cells with hydrogen peroxide results in a marked release of histamine. Maximal release is observed with 0.05-0.1 mM H(2)O(2), but higher concentrations of H(2)O(2) instead suppresses the release. Histamine release starts after about 2 min of lag time and reaches a plateau in about 10 min. Hydrogen peroxide-induced release does not exceed 50-60 per cent of total histamine if the incubations are prolonged or additional H(2)O(2) is given at 10 min. This would be explained by the fact that H(2)O(2) causes impairment of the histamine releasing system of mast cells simultaneously with the release of histamine. Hydrogen peroxide-induced release is not due to nonspecific lysis of the cells because lactate dehydrogenase, a cytoplasmic enzyme, is not liberated during the reaction. The reaction requires the presence of Ca(2+), is enhanced by D(2)O and suppressed by colchicine. It is not, however, affected by dibutyryl cAMP or dibutyryl cGMP. No significant alteration of intracellular levels of cyclic AMP and cyclic GMP is observed during the incubation of mast cells with 0.1 mM H(2)O(2). These results indicate that microtubular functions would be involved in the releasing reaction although they are not under the control of cyclic nucleotides. Microscopic observation shows that H(2)O(2)-induced release is accompanied by degranulation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0006-2952(80)90550-xDOI Listing

Publication Analysis

Top Keywords

mast cells
16
hydrogen peroxide-induced
12
release histamine
12
release
9
histamine release
8
peroxide-induced release
8
histamine
6
cells
5
h2o2
5
properties hydrogen
4

Similar Publications

Purpose: To evaluate the effect of the topical application of the ethanol extract (EESL) and the hydroethanolic fraction (HFSL) of ripe Solanum lycocarpum fruit on the healing of experimentally-induced wounds in mice.

Methods: The EESL and HFSL obtained from ripe fruit of the species S. lycocarpum were obtained by percolation with ethanol.

View Article and Find Full Text PDF

Allergies are closely associated with sex-related hormonal variations that influence immune function, leading to distinct symptom profiles. Similar sex-based differences are observed in other immune disorders, such as autoimmune diseases. In allergies, women exhibit a higher prevalence of atopic conditions, such as allergic asthma and eczema, in comparison to men.

View Article and Find Full Text PDF

Introduction: The role of mast cells (MCs) in clear cell renal carcinoma (ccRCC) is unclear, and comprehensive single-cell studies of ccRCC MCs have not yet been performed.

Methods: To investigate the heterogeneity and effects of MCs in ccRCC, we studied single-cell transcriptomes from four ccRCC patients, integrating both single-cell sequencing and bulk tissue sequencing data from online sequencing databases, followed by validation via spatial transcriptomics and multiplex immunohistochemistry (mIHC).

Results: We identified four MC signature genes (TPSB2, TPSAB1, CPA3, and HPGDS).

View Article and Find Full Text PDF

Today, in the modern world, allergic diseases, also described as atopic allergies, are classified as a type of multifactorial disorder due to the complex interplay between genetics, environment, and socioeconomic factors that influence the disease's manifestation, severity, and one's predisposition to allergic diseases. It is undeniable that many reported studies have pointed out that the mast cell is one of the leading key players involved in triggering an allergic reaction. To improve our understanding of the molecular and cellular mechanisms underlying allergy, various mast cell lines have been employed in vitro to study the pathogenesis of allergic diseases for the past decades.

View Article and Find Full Text PDF

Antibodies used for cancer therapy are monoclonal IgGs, but tumor-targeting IgE antibodies have shown enhanced effector cell potency against cancer in preclinical models. Research-grade recombinant IgE antibodies have been generated and studied for several decades. The recent Phase 1 clinical trial of the first-in-class MOv18 IgE, however, necessitated the inaugural process development and scaled manufacture of a recombinant IgE to clinical quality standards.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!